Tag: Rare disease clinical trial decentralization
CRISPR Licensing, Gene Therapy Supply Chain, Oligonucleotide Dosing, and Rare Disease Trials: Strategies for Optimization and Decentralization
Are you looking to invest in or optimize your strategies in CRISPR licensing, gene therapy supply chain, oligonucleotide dosing, or rare disease trials? A 2023 SEMrush study shows the global gene – editing market, led by CRISPR, is set to reach billions. Leading sources like Pharma Intelligence and biotech industry analysis tools back the importance